Adventrx Pharmaceuticals, Inc.

Clearance granted in U.K. for CoFactor phase IIb colorectal cancer trial

Published in Pharma Law Weekly, May 17th, 2005

Adventrx Pharmaceuticals, Inc., (ANX) announced that it has received clearance from the Medicines and Healthcare products Regulatory Agency (MHRA) to begin an international phase IIb randomized controlled clinical trial using CoFactor with 5-fluorouracil (5-FU) in metastatic colorectal cancer in the United Kingdom.

The company expects to begin patient enrollment for this trial by the end of April 2005. The trial will be conducted at clinical sites in the European Union (EU) and countries outside of the EU following regulatory and ethics approval in each country.

"This clearance comes on the heels of meeting our primary clinical endpoint for response...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2005-05-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry